1-20 of 179
Keywords: Multiple myeloma
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025)
Published Online: 24 April 2025
.... Case Presentation: We describe the successful management of AHA secondary to multiple myeloma (MM) using emicizumab and targeted anti-myeloma therapy. The patient initially responded to bortezomib-dexamethasone but required teclistamab due to disease progression. Emicizumab maintained hemostatic...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025)
Published Online: 11 February 2025
...Meng-Jun Huang; Qing-Yi Zeng; Dan Chen; Chun-Xia Yang; Ying Yang; Man Zhou; Fen-Li Zhang; Qiu-Han Bian; Xiao-Yan Yang Introduction: Many reports indicate that the occurrence of multiple myeloma (MM) is closely related to inflammation and immunity. Although the survival rates have been gradually...
Journal Articles
Journal Articles
Acta Haematol (2025) 148 (3): 315–329.
Published Online: 25 November 2024
...Muhammad Faisal Aslam; Asfand Yar Cheema; Daniyal Shahid; Bibi Maryam; Debduti Mukhopadhyay; Mishaal Munir; Ali Najam; Hossam M. Ali; Qaiser Bashir; Faiz Anwer Background: Advances in novel therapies have improved outcomes for multiple myeloma (MM) patients and the use of allo-SCT has decreased...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025) 148 (2): 135–147.
Published Online: 10 May 2024
...Julie Barberio; Timothy L. Lash; Ajay K. Nooka; Ashley I. Naimi; Rachel E. Patzer; Christopher Kim Introduction: Most multiple myeloma (MM) patients experience cytopenias, likely driven by both disease and treatment-related factors. Immunomodulatory agents (IMiDs), which form the backbone of most...
Journal Articles
Acta Haematol (2025) 148 (3): 300–314.
Published Online: 08 May 2024
... maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for the treatment of relapsed and refractory multiple myeloma (RRMM). Summary: These therapies offer unprecedented responses in RRMM but present new challenges including cytokine release syndrome (CRS...
Journal Articles
Acta Haematol (2025) 148 (3): 289–299.
Published Online: 06 May 2024
...Inbar Cohen; Iuliana Vaxman; Morie A. Gertz Background: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become part of standard of care (SOC) in newly diagnosed multiple myeloma. In this review, we provide a historical perspective on ASCT since its introduction...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025) 148 (1): 48–57.
Published Online: 16 April 2024
... remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence. Methods: A comprehensive analysis was conducted on 309 consecutive patients diagnosed with either multiple myeloma or pPCL, utilizing peripheral blood smears stained with Wright-Giemsa...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2025) 148 (1): 36–47.
Published Online: 25 March 2024
...Jiaqi Shao; Enfan Zhang; Haoguang Chen; Zhen Cai; Mengmeng Dong Introduction: Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Abnormally cloned plasma cells secrete large amounts of monoclonal immunoglobulins in the bone marrow of MM patients. Serum urea nitrogen (sUN...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2024) 147 (6): 729–734.
Published Online: 06 March 2024
...Alexander D. Heini; Vera Ulrike Bacher; Dilara Akhoundova; Katja Seipel; Thomas Pabst Introduction: Bispecific antibodies have meaningfully expanded the therapeutic armamentarium in multiple myeloma. Talquetamab is a CD3+ T-cell-redirecting antibody targeting GPRC5D, which is expressed on multiple...
Journal Articles
Acta Haematol (2023) 146 (5): 419–423.
Published Online: 20 June 2023
... allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma...
Journal Articles
Acta Haematol (2023) 146 (5): 424–430.
Published Online: 16 June 2023
...Salvatore Troisi; Valentina Giudice; Mario Troisi; Denise Morini; Andrea Crudele; Bianca Cuffa; Carmine Selleri; Bianca Serio Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available...
Journal Articles
Acta Haematol (2023) 146 (2): 125–136.
Published Online: 20 April 2023
...Kazuhito Suzuki; Morio Matsumoto; Yasushi Hiramatsu; Naoki Takezako; Yotaro Tamai; Kenshi Suzuki Introduction: Elotuzumab and lenalidomide plus dexamethasone (ERd) is a standard salvage chemotherapy for multiple myeloma, and elotuzumab is commonly administered every 2 weeks after cycle 3...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2022) 145 (6): 619–626.
Published Online: 29 July 2022
... multiple myeloma (SMM, n = 2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n = 6). Six patients were on tyrosine kinase inhibitor treatment, 2 were in treatment-free remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2022) 145 (3): 326–333.
Published Online: 24 November 2021
...Josefin Hidman; Anders Larsson; Måns Thulin; Torbjörn Karlsson Introduction: In multiple myeloma, there is an increase in bone marrow microvascular density and enhanced renal lymphangiogenesis. Increased levels of the proangiogenic protein growth differentiation factor-15 (GDF15) have previously...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2021) 144 (5): 542–550.
Published Online: 30 March 2021
...Congyang Huang; Hanshan Liu; Li Jia; Min Lu; Suyun Hu Background/Aim: The impacts of health insurance status on survival outcomes in multiple myeloma (MM) have not been addressed in depth. The present study was conducted to identify definite relationships of cancer-specific survival (CSS...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2021) 144 (5): 519–527.
Published Online: 25 February 2021
...Hareth Nahi; Göran Walinder; Vishal Patel; Ying Qu; Aaron Levine; Istvan Majer; Lucie Kutikova; Eva Hellqvist Franck; Maria K. Svensson; Markus Hansson Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world...